{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:55:57Z","timestamp":1793361357662,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","award":["FDM202006011286"],"award-info":[{"award-number":["FDM202006011286"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale pour la Recherche sur le SIDA et les h\u00e9patites virales","doi-asserted-by":"crossref","award":["ECTZ 105732"],"award-info":[{"award-number":["ECTZ 105732"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04613-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:01:18Z","timestamp":1751364078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased IFN responses drive myeloid cell activation in people living with HIV-1"],"prefix":"10.1038","volume":"15","author":[{"given":"L\u00e9o","family":"Pla\u00e7ais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candie","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"d\u2019Urbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelliah","family":"Mouanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bourdic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bredel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bourdic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Jacquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"M\u00fcller-Tr\u00fctwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"4613_CR1","unstructured":"HIV. \u2013 Number of people (all ages) living with HIV. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/estimated-number-of-people--living-with-hiv. Retrieved 7 April (2024)."},{"key":"4613_CR2","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford, S. et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a National observational cohort. Lancet Public. Health. 2, e35\u2013e46 (2017).","journal-title":"Lancet Public. Health"},{"key":"4613_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","volume":"39","author":"SG Deeks","year":"2013","unstructured":"Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633\u2013645 (2013).","journal-title":"Immunity"},{"key":"4613_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/imr.12065","volume":"254","author":"NR Klatt","year":"2013","unstructured":"Klatt, N. R., Chomont, N., Douek, D. C. & Deeks, S. G. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol. Rev. 254, 326\u2013342 (2013).","journal-title":"Immunol. Rev."},{"key":"4613_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12079","volume":"254","author":"M Paiardini","year":"2013","unstructured":"Paiardini, M. & M\u00fcller-Trutwin, M. HIV-associated chronic immune activation. Immunol. Rev. 254, 78\u2013101 (2013).","journal-title":"Immunol. Rev."},{"key":"4613_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"INSIGHT START Study Group","year":"2015","unstructured":"INSIGHT START Study Group et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl. J. Med. 373, 795\u2013807 (2015).","journal-title":"N Engl. J. Med."},{"key":"4613_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12889-021-10421-8","volume":"21","author":"A Rodrigues","year":"2021","unstructured":"Rodrigues, A. et al. Late initiation of antiretroviral therapy: inequalities by educational level despite universal access to care and treatment. BMC Public. Health. 21, 389 (2021).","journal-title":"BMC Public. Health"},{"key":"4613_CR8","doi-asserted-by":"publisher","first-page":"e0180843","DOI":"10.1371\/journal.pone.0180843","volume":"12","author":"TV Fatukasi","year":"2017","unstructured":"Fatukasi, T. V. et al. Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. PloS One. 12, e0180843 (2017).","journal-title":"PloS One"},{"key":"4613_CR9","doi-asserted-by":"publisher","first-page":"e0271127","DOI":"10.1371\/journal.pone.0271127","volume":"17","author":"B Bantie","year":"2022","unstructured":"Bantie, B. et al. Delayed ART initiation in test and treat era and its associated factors among adults receiving antiretroviral therapy at public health institutions in Northwest ethiopia: A multicenter cross-sectional study. PLOS ONE. 17, e0271127 (2022).","journal-title":"PLOS ONE"},{"key":"4613_CR10","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S2352-3018(22)00040-6","volume":"9","author":"TL Hiv","year":"2022","unstructured":"Hiv, T. L. Time to tackle late diagnosis. Lancet HIV. 9, e139 (2022).","journal-title":"Lancet HIV"},{"key":"4613_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","volume":"107","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: challenges of immunological non-responders. J. Leukoc. Biol. 107, 597\u2013612 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"4613_CR12","doi-asserted-by":"publisher","first-page":"e014873","DOI":"10.1161\/JAHA.119.014873","volume":"9","author":"B Titanji","year":"2020","unstructured":"Titanji, B., Gavegnano, C., Hsue, P., Schinazi, R. & Marconi, V. C. Targeting inflammation to reduce atherosclerotic cardiovascular risk in people with HIV infection. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 9, e014873 (2020).","journal-title":"J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis."},{"key":"4613_CR13","doi-asserted-by":"crossref","unstructured":"Swainson, L. A. et al. IFN-\u03b1 Blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight 7:e153046 .","DOI":"10.1172\/jci.insight.153046"},{"key":"4613_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1172\/JCI89488","volume":"127","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Targeting type I interferon\u2013mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127, 260\u2013268 (2017).","journal-title":"J. Clin. Invest."},{"key":"4613_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1172\/JCI90745","volume":"127","author":"L Cheng","year":"2017","unstructured":"Cheng, L. et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J. Clin. Invest. 127, 269\u2013279 (2017).","journal-title":"J. Clin. Invest."},{"key":"4613_CR16","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/infdis\/jir659","volume":"204","author":"S Fernandez","year":"2011","unstructured":"Fernandez, S. et al. CD4\u2009+\u2009T-Cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of Interferon-Stimulated genes in CD4\u2009+\u2009T cells. J. Infect. Dis. 204, 1927\u20131935 (2011).","journal-title":"J. Infect. Dis."},{"key":"4613_CR17","doi-asserted-by":"crossref","unstructured":"Dunham, R. M. et al. Discordance between peripheral and colonic markers of inflammation during suppressive ART. J. Acquir. Immune. Defic. Syndr. 1999 (65), 133\u2013141 (2014).","DOI":"10.1097\/01.qai.0000437172.08127.0b"},{"key":"4613_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/infdis\/jir507","volume":"204","author":"MM Lederman","year":"2011","unstructured":"Lederman, M. M. et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204, 1217\u20131226 (2011).","journal-title":"J. Infect. Dis."},{"key":"4613_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. 5. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"4613_CR20","doi-asserted-by":"publisher","first-page":"e1006740","DOI":"10.1371\/journal.ppat.1006740","volume":"13","author":"C Gavegnano","year":"2017","unstructured":"Gavegnano, C. et al. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLOS Pathog. 13, e1006740 (2017).","journal-title":"PLOS Pathog"},{"key":"4613_CR21","doi-asserted-by":"publisher","first-page":"720697","DOI":"10.3389\/fimmu.2021.720697","volume":"12","author":"LR de Armas","year":"2021","unstructured":"de Armas, L. R. et al. The effect of JAK1\/2 inhibitors on HIV reservoir using primary lymphoid cell model of HIV latency. Front. Immunol. 12, 720697 (2021).","journal-title":"Front. Immunol."},{"key":"4613_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"AR Tenorio","year":"2014","unstructured":"Tenorio, A. R. et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J. Infect. Dis. 210, 1248\u20131259 (2014).","journal-title":"J. Infect. Dis."},{"key":"4613_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler, N. G. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780\u2013790 (2011).","journal-title":"J. Infect. Dis."},{"key":"4613_CR24","doi-asserted-by":"publisher","first-page":"13436","DOI":"10.1038\/ncomms13436","volume":"7","author":"S Geng","year":"2016","unstructured":"Geng, S. et al. The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis. Nat. Commun. 7, 13436 (2016).","journal-title":"Nat. Commun."},{"key":"4613_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/QAD.0b013e328351f756","volume":"26","author":"AC Hearps","year":"2012","unstructured":"Hearps, A. C. et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS Lond. Engl. 26, 843\u2013853 (2012).","journal-title":"AIDS Lond. Engl."},{"key":"4613_CR26","doi-asserted-by":"publisher","first-page":"e55279","DOI":"10.1371\/journal.pone.0055279","volume":"8","author":"GE Martin","year":"2013","unstructured":"Martin, G. E. et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PloS One. 8, e55279 (2013).","journal-title":"PloS One"},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1182\/blood-2002-10-3065","volume":"101","author":"D Trabattoni","year":"2003","unstructured":"Trabattoni, D. et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101, 2514\u20132520 (2003).","journal-title":"Blood"},{"key":"4613_CR28","doi-asserted-by":"publisher","first-page":"e0258122","DOI":"10.1371\/journal.pone.0258122","volume":"16","author":"W Tamene","year":"2021","unstructured":"Tamene, W. et al. PDL1 expression on monocytes is associated with plasma cytokines in tuberculosis and HIV. PLOS ONE. 16, e0258122 (2021).","journal-title":"PLOS ONE"},{"key":"4613_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","volume":"10","author":"R Fromentin","year":"2019","unstructured":"Fromentin, R. et al. PD-1 Blockade potentiates HIV latency reversal ex vivo in CD4\u2009+\u2009T cells from ART-suppressed individuals. Nat. Commun. 10, 814 (2019).","journal-title":"Nat. Commun."},{"key":"4613_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.imlet.2018.09.007","volume":"203","author":"A Le\u00f3n-Flores","year":"2018","unstructured":"Le\u00f3n-Flores, A., Del R\u00edo Estrada, P. M., \u00c1lvarez-Garc\u00eda, L. X., Piten-Isidro, E. & Reyes-Ter\u00e1n, G. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1\u2009+\u2009individuals. Immunol. Lett. 203, 70\u201379 (2018).","journal-title":"Immunol. Lett."},{"key":"4613_CR31","doi-asserted-by":"publisher","first-page":"e20065","DOI":"10.1097\/MD.0000000000020065","volume":"99","author":"J Avenda\u00f1o-Ortiz","year":"2020","unstructured":"Avenda\u00f1o-Ortiz, J. et al. Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure. Med. (Baltim). 99, e20065 (2020).","journal-title":"Med. (Baltim)."},{"key":"4613_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga, R. et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754\u2013761 (2016).","journal-title":"Nat. Med."},{"key":"4613_CR33","doi-asserted-by":"publisher","first-page":"e26320","DOI":"10.1371\/journal.pone.0026320","volume":"6","author":"A Eastburn","year":"2011","unstructured":"Eastburn, A. et al. Association of low level viremia with inflammation and mortality in HIV-Infected adults. PLOS ONE. 6, e26320 (2011).","journal-title":"PLOS ONE"},{"key":"4613_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","volume":"6","author":"GP Hartley","year":"2018","unstructured":"Hartley, G. P., Chow, L., Ammons, D. T., Wheat, W. H. & Dow, S. W. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol. Res. 6, 1260\u20131273 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"4613_CR35","doi-asserted-by":"publisher","first-page":"108258","DOI":"10.1016\/j.celrep.2020.108258","volume":"33","author":"ED Lucas","year":"2020","unstructured":"Lucas, E. D. et al. PD-L1 reverse signaling in dermal dendritic cells promotes dendritic cell migration required for skin immunity. Cell. Rep. 33, 108258 (2020).","journal-title":"Cell. Rep."},{"key":"4613_CR36","doi-asserted-by":"publisher","first-page":"e1007401","DOI":"10.1371\/journal.pcbi.1007401","volume":"15","author":"V Zheltkova","year":"2019","unstructured":"Zheltkova, V., Argilaguet, J., Peligero, C., Bocharov, G. & Meyerhans, A. Prediction of PD-L1 Inhibition effects for HIV-infected individuals. PLOS Comput. Biol. 15, e1007401 (2019).","journal-title":"PLOS Comput. Biol."},{"key":"4613_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/infdis\/jir214","volume":"204","author":"TH Burdo","year":"2011","unstructured":"Burdo, T. H. et al. Soluble CD163 made by monocyte\/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after Anti-retroviral therapy. J. Infect. Dis. 204, 154\u2013163 (2011).","journal-title":"J. Infect. Dis."},{"key":"4613_CR38","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.ebiom.2020.103129","volume":"62","author":"S Novelli","year":"2020","unstructured":"Novelli, S. et al. Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection. EBioMedicine 62, 103129 (2020).","journal-title":"EBioMedicine"},{"key":"4613_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-024-00144-6","volume":"10","author":"RD Reitsema","year":"2024","unstructured":"Reitsema, R. D., Kumawat, A. K., Hesselink, B-C., van Baarle, D. & van Sleen, Y. Effects of ageing and frailty on Circulating monocyte and dendritic cell subsets. Npj Aging. 10, 1\u20136 (2024).","journal-title":"Npj Aging"},{"key":"4613_CR40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4049\/jimmunol.1700148","volume":"199","author":"TU Metcalf","year":"2017","unstructured":"Metcalf, T. U. et al. Human monocyte subsets are transcriptionally and functionally altered in aging in response to pattern recognition receptor agonists. J. Immunol. 199, 1405\u20131417 (2017).","journal-title":"J. Immunol."},{"key":"4613_CR41","doi-asserted-by":"publisher","first-page":"e0132061","DOI":"10.1371\/journal.pone.0132061","volume":"10","author":"MM Lissner","year":"2015","unstructured":"Lissner, M. M. et al. Age-Related gene expression differences in monocytes from human neonates, young adults, and older adults. PLOS ONE. 10, e0132061 (2015).","journal-title":"PLOS ONE"},{"key":"4613_CR42","doi-asserted-by":"publisher","first-page":"eaan2392","DOI":"10.1126\/scisignal.aan2392","volume":"10","author":"RD Molony","year":"2017","unstructured":"Molony, R. D. et al. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal. 10, eaan2392 (2017).","journal-title":"Sci. Signal."},{"key":"4613_CR43","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1182\/blood-2008-11-190231","volume":"113","author":"GAD Hardy","year":"2009","unstructured":"Hardy, G. A. D. et al. Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood 113, 5497\u20135505 (2009).","journal-title":"Blood"},{"key":"4613_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature13554","volume":"511","author":"NG Sandler","year":"2014","unstructured":"Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601\u2013605 (2014).","journal-title":"Nature"},{"key":"4613_CR45","doi-asserted-by":"publisher","unstructured":"Sugawara, S. et al. People with HIV-1 demonstrate type 1 interferon refractoriness associated with upregulated USP18. J. Virol. 95, e01777-20 https:\/\/doi.org\/10.1128\/JVI.01777-20 (2021).","DOI":"10.1128\/JVI.01777-20"},{"key":"4613_CR46","doi-asserted-by":"publisher","first-page":"e56527","DOI":"10.1371\/journal.pone.0056527","volume":"8","author":"GAD Hardy","year":"2013","unstructured":"Hardy, G. A. D. et al. Interferon-\u03b1 is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PloS One. 8, e56527 (2013).","journal-title":"PloS One"},{"key":"4613_CR47","doi-asserted-by":"crossref","unstructured":"Le Buanec, H. et al. 2024. IFN\u03b1 induces CCR5 in CD4\u2009+\u2009T cells of HIV patients causing pathogenic elevation. Commun. Med. 4:1\u201313 .","DOI":"10.1038\/s43856-024-00453-7"},{"key":"4613_CR48","doi-asserted-by":"publisher","first-page":"E9162","DOI":"10.1073\/pnas.1720930115","volume":"115","author":"R Kamada","year":"2018","unstructured":"Kamada, R. et al. Interferon stimulation creates chromatin marks and establishes transcriptional memory. Proc. Natl. Acad. Sci. 115, E9162\u2013E9171 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"4613_CR49","doi-asserted-by":"crossref","unstructured":"Knoll, R. et al. Identification of drug candidates targeting monocyte reprogramming in people living with HIV. (2023). Front Immunol 14.","DOI":"10.3389\/fimmu.2023.1275136"},{"key":"4613_CR50","doi-asserted-by":"crossref","unstructured":"van der Heijden, W. A. et al. Mast Q. De Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. (2021). JCI Insight 6.","DOI":"10.1172\/jci.insight.145928"},{"key":"4613_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40246-019-0247-x","volume":"13","author":"DR Lorenz","year":"2019","unstructured":"Lorenz, D. R., Misra, V. & Gabuzda, D. Transcriptomic analysis of monocytes from HIV-positive men on antiretroviral therapy reveals effects of tobacco smoking on interferon and stress response systems associated with depressive symptoms. Hum. Genomics. 13, 59 (2019).","journal-title":"Hum. Genomics"},{"key":"4613_CR52","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1038\/s41598-018-23841-1","volume":"8","author":"MS Esp\u00edndola","year":"2018","unstructured":"Esp\u00edndola, M. S. et al. Epigenetic alterations are associated with monocyte immune dysfunctions in HIV-1 infection. Sci. Rep. 8, 5505 (2018).","journal-title":"Sci. Rep."},{"key":"4613_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-018-3643-2","volume":"19","author":"D Watanabe","year":"2019","unstructured":"Watanabe, D. et al. Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-\u03b3: a multicenter observational study. BMC Infect. Dis. 19, 11 (2019).","journal-title":"BMC Infect. Dis."},{"key":"4613_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1086\/655229","volume":"202","author":"E Cassol","year":"2010","unstructured":"Cassol, E. et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202, 723\u2013733 (2010).","journal-title":"J. Infect. Dis."},{"key":"4613_CR55","doi-asserted-by":"crossref","unstructured":"Sachdeva, M., Fischl, M. A., Pahwa, R., Sachdeva, N. & Pahwa, S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr. 1999 (54), 447\u2013454 (2010).","DOI":"10.1097\/QAI.0b013e3181e0c7d0"},{"key":"4613_CR56","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/eji.200838285","volume":"38","author":"X Wang","year":"2008","unstructured":"Wang, X. et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur. J. Immunol. 38, 3226\u20133236 (2008).","journal-title":"Eur. J. Immunol."},{"key":"4613_CR57","doi-asserted-by":"crossref","unstructured":"Xiao, W., Klement, J. D., Lu, C., Ibrahim, M. L. & Liu, K. IFNAR1 controls autocrine type I IFN regulation of PD-L1 expression in myeloid-derived suppressor cells. J. Immunol. Baltim. Md. 1950 (201), 264\u2013277 (2018).","DOI":"10.4049\/jimmunol.1800129"},{"key":"4613_CR58","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","volume":"9","author":"AV Bazhin","year":"2018","unstructured":"Bazhin, A. V., von Ahn, K., Fritz, J., Werner, J. & Karakhanova, S. Interferon-\u03b1 Up-Regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front. Immunol. 9, 2129 (2018).","journal-title":"Front. Immunol."},{"key":"4613_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"G Sch\u00f6nrich","year":"2019","unstructured":"Sch\u00f6nrich, G. & Raftery, M. J. The PD-1\/PD-L1 Axis and virus infections: A delicate balance. Front. Cell. Infect. Microbiol. 9, 207 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"4613_CR60","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 Blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"4613_CR61","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","volume":"215","author":"CL Gay","year":"2017","unstructured":"Gay, C. L. et al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J. Infect. Dis. 215, 1725\u20131733 (2017).","journal-title":"J. Infect. Dis."},{"key":"4613_CR62","doi-asserted-by":"publisher","first-page":"e1973","DOI":"10.1093\/cid\/ciaa1530","volume":"73","author":"TA Rasmussen","year":"2021","unstructured":"Rasmussen, T. A. et al. Impact of Anti-PD-1 and Anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with Cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study. Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am. 73, e1973\u2013e1981 (2021).","journal-title":"Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am."},{"key":"4613_CR63","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.4049\/jimmunol.208.Supp.52.05","volume":"208","author":"JL Shirley","year":"2022","unstructured":"Shirley, J. L., Forward, T., Schafer, J. B., Lucas, E. D. & Tamburini, B. PD-L1 back signaling manipulates IL-6 signaling to coordinate innate immune responses. J. Immunol. 208, 5205 (2022).","journal-title":"J. Immunol."},{"key":"4613_CR64","doi-asserted-by":"publisher","first-page":"e129353","DOI":"10.1172\/jci.insight.129353","volume":"5","author":"N Bar","year":"2020","unstructured":"Bar, N. et al. Differential effects of PD-L1 versus PD-1 Blockade on myeloid inflammation in human cancer. JCI Insight. 5, e129353 (2020).","journal-title":"JCI Insight"},{"key":"4613_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","volume":"68","author":"KM Mahoney","year":"2019","unstructured":"Mahoney, K. M. et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol. Immunother. 68, 421\u2013432 (2019).","journal-title":"Cancer Immunol. Immunother"},{"key":"4613_CR66","doi-asserted-by":"crossref","unstructured":"Leite Pereira, A., Tchitchek, N., Lambotte, O., Le Grand, R. & Cosma, A. Characterization of leukocytes from HIV-ART patients using combined cytometric profiles of 72 cell markers. Front. Immunol. 10. (2019).","DOI":"10.3389\/fimmu.2019.01777"},{"key":"4613_CR67","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. 9. Nat. Rev. Immunol. 7, 678\u2013689 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"4613_CR68","first-page":"6105","volume":"171","author":"JL Dunne","year":"2003","unstructured":"Dunne, J. L., Collins, R. G., Beaudet, A. L., Ballantyne, C. M. & Ley, K. Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J. Immunol. Baltim. Md. 1950. 171, 6105\u20136111 (2003).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"4613_CR69","doi-asserted-by":"publisher","first-page":"e0139474","DOI":"10.1371\/journal.pone.0139474","volume":"10","author":"MR McCausland","year":"2015","unstructured":"McCausland, M. R. et al. Altered monocyte phenotype in HIV-1 infection tends to normalize with Integrase-Inhibitor-Based antiretroviral therapy. PLOS ONE. 10, e0139474 (2015).","journal-title":"PLOS ONE"},{"key":"4613_CR70","first-page":"1249","volume":"132","author":"S Becker","year":"1984","unstructured":"Becker, S. Interferons as modulators of human monocyte-macrophage differentiation. I. Interferon-gamma increases HLA-DR expression and inhibits phagocytosis of zymosan. J. Immunol. Baltim. Md. 1950. 132, 1249\u20131254 (1984).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"4613_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","volume":"16","author":"C Gavegnano","year":"2019","unstructured":"Gavegnano, C. et al. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. J. Neuroinflammation. 16, 182 (2019).","journal-title":"J. Neuroinflammation"},{"key":"4613_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2018.03.004","volume":"40","author":"N No\u00ebl","year":"2018","unstructured":"No\u00ebl, N. et al. Interferon-associated therapies toward HIV control: the back and forth. Cytokine Growth Factor. Rev. 40, 99\u2013112 (2018).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"4613_CR73","doi-asserted-by":"crossref","unstructured":"Zanin, N., Viaris de Lesegno, C., Lamaze, C. & Blouin, C. M. Interferon receptor trafficking and signaling: journey to the cross roads. Front. Immunol. 11. (2021).","DOI":"10.3389\/fimmu.2020.615603"},{"key":"4613_CR74","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208\u2013e219 (2019).","journal-title":"Lancet Rheumatol."},{"key":"4613_CR75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes, I. B. et al. Comparison of baricitinib, upadacitinib, and Tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res. Ther. 21, 183 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"4613_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/cid\/ciab212","volume":"74","author":"VC Marconi","year":"2022","unstructured":"Marconi, V. C. et al. Randomized trial of ruxolitinib in Antiretroviral-Treated adults with human immunodeficiency virus. Clin. Infect. Dis. 74, 95\u2013104 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"4613_CR77","doi-asserted-by":"publisher","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","volume":"356","author":"A-C Villani","year":"2017","unstructured":"Villani, A-C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).","journal-title":"Science"},{"key":"4613_CR78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jir.2017.0076","volume":"37","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Expression pattern of individual IFNA subtypes in chronic HIV infection. J. Interferon Cytokine Res. 37, 541\u2013549 (2017).","journal-title":"J. Interferon Cytokine Res."},{"key":"4613_CR79","doi-asserted-by":"publisher","unstructured":"Schlaepfer, E. et al. Dose-Dependent differences in HIV Inhibition by different interferon alpha subtypes while having overall similar biologic effects. mSphere 4 https:\/\/doi.org\/10.1128\/msphere.00637-18 (2019).","DOI":"10.1128\/msphere.00637-18"},{"key":"4613_CR80","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1084\/jem.187.12.2103","volume":"187","author":"M Munder","year":"1998","unstructured":"Munder, M., Mallo, M., Eichmann, K. & Modolell, M. Murine macrophages secrete interferon gamma upon combined stimulation with Interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J. Exp. Med. 187, 2103\u20132108 (1998).","journal-title":"J. Exp. Med."},{"key":"4613_CR81","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves, P. G. et al. JAK selectivity and the implications for clinical Inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, Tofacitinib and baricitinib. Ann. Rheum. Dis. 80, 865\u2013875 (2021).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04613-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04613-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04613-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:26:12Z","timestamp":1751369172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04613-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04613-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20627"}}